Octreotid Hexal (Octreotide)

Octreotide, the active ingredient in Octreotid Hexal, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed to control hormone excess in conditions such as acromegaly, carcinoid syndrome, VIPoma and other hormone‑secreting tumors in adult patients.

GNH USA supplies Octreotid Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreotide acts on somatostatin receptors to modulate hormone secretion in several endocrine disorders. - Acromegaly: reduces growth hormone and IGF‑1 levels, helping to control disease activity. - Carcinoid syndrome: diminishes flushing and diarrhea by inhibiting serotonin release. - VIPoma: alleviates watery diarrhea and electrolyte loss through VIP suppression. - Hormone‑secreting tumors: curbs excess hormone production, improving clinical symptoms.

Octreotide may be associated with a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Injection site pain or erythema. - Gastrointestinal disturbances such as nausea, abdominal pain, or constipation. - Gallbladder sludge or gallstones. - Hyperglycemia or hypoglycemia. - Headache.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Pancreatitis. - Cardiac arrhythmias. - Severe hyperglycemia requiring medical intervention. - Acute cholecystitis. - Thromboembolic events.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications. - Renal impairment: adjust monitoring as the drug is cleared renally. - Hepatic dysfunction: observe for altered metabolism and possible accumulation. - Diabetes mellitus: monitor blood glucose closely due to possible hyper‑ or hypoglycemia. - Gallbladder disease: assess risk of gallstone formation during long‑term use. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide can influence the pharmacokinetics or pharmacodynamics of several concomitant medicines.

Major Interactions (Avoid): - Cyclosporine: may increase cyclosporine levels, risking nephrotoxicity. - Octreotide and insulin secretagogues: can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy due to altered hormone metabolism. - Somatostatin analogs combined with other hormone‑suppressing agents: monitor for additive effects. - Antidiabetic agents: adjust glucose monitoring as octreotide may mask hyperglycemia.